P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Book ChapterDOI
Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma: Principles of Identification and Management
TL;DR: This chapter focuses on the identification, characterization, and management of bortezomib-induced peripheral neuropathy.
Journal ArticleDOI
Daratumumab (DARA) + lenalidomide, bortezomib, and dexamethasone (RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM): A post hoc analysis of sustained minimal residual disease (MRD) negativity from GRIFFIN.
Cesar Rodriguez,Jonathan L. Kaufman,Jacob P. Laubach,Douglas W. Sborov,Brandi Reeves,Ajai Chari,Rebecca Silbermann,Luciano J. Costa,Larry D. Anderson,Nitya Nathwani,Nina Shah,Naresh Bumma,Andrzej Jakubowiak,Robert Z. Orlowski,Huiling Pei,Annelore Cortoos,Sharmila Patel,Thomas S. Lin,Paul G. Richardson,Peter M. Voorhees +19 more
TL;DR: MRD data in GRIFFIN show that the addition of DARA to RVd induction/consolidation and R maintenance may lead to durable MRD-negativity rates in pts with transplant-eligible NDMM with high cytogenetic risk, ISS stage III, and those who achieve ≥CR or sCR, however larger studies are needed.
Journal ArticleDOI
Cardiovascular safety profile of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor: Results from two independent phase I trials in patients with advanced cancer
TL;DR: It is shown that IPI-504 administration was associated with transient, dose-related bradycardia and PR interval lengthening, suggestive of autonomic effects associated with the drug infusion, and appropriate monitoring of heart rate immediately post-infusion is recommended during further studies with IPi-504.
Journal Article
Current antibody-based therapies for the treatment of multiple myeloma.
TL;DR: An overview of the currently available monoclonal antibody treatments for multiple myeloma can be found in this paper, where the authors discuss the clinical value, significant potential, and possible limitations of these immunotherapeutic approaches to driving deeper responses and achieving longer overall survival among patients with a challenging disease.
Journal ArticleDOI
High-Resolution Assessment of Gains and Losses of Chromosomes in Patients with Multiple Myeloma Treated with Bortezomib.
Hadi Danaee,Barb Bryant,Steve Roels,Dave Lichter,Eric Koening,William L. Trepicchio,Anthony Boral,Paul G. Richardson,Yan Meng,Peter Leif Bergsagel,Pieter Sonneveld,Annemiek Broyl,Constantine S. Mitsiades,Wee Joo Chng,Kenneth C. Anderson,George Mulligan +15 more
TL;DR: It was found that 35% of this relapsed multiple myeloma population exhibited a hyperdiploid genome characterized by gains of chromosomes 3, 5, 7, 9, 11, 15, and 19, and a correlation of response to bortezomib therapy in patients with differential gains and losses at the chromosomal level is ongoing.